- Home
- OABI vs NRO Comparison
OABI vs NRO Comparison
Compare OABI & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- NRO
- Stock Information
- Founded
- OABI 2012
- NRO 2003
- Country
- OABI United States
- NRO United States
- Employees
- OABI 114
- NRO N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- NRO Finance/Investors Services
- Sector
- OABI Health Care
- NRO Finance
- Exchange
- OABI Nasdaq
- NRO Nasdaq
- Market Cap
- OABI 239.0M
- NRO 199.6M
- IPO Year
- OABI N/A
- NRO N/A
- Fundamental
- Price
- OABI $1.65
- NRO $3.17
- Analyst Decision
- OABI Strong Buy
- NRO
- Analyst Count
- OABI 3
- NRO 0
- Target Price
- OABI $6.67
- NRO N/A
- AVG Volume (30 Days)
- OABI 525.9K
- NRO 239.4K
- Earning Date
- OABI 11-04-2025
- NRO 01-01-0001
- Dividend Yield
- OABI N/A
- NRO 11.41%
- EPS Growth
- OABI N/A
- NRO N/A
- EPS
- OABI N/A
- NRO N/A
- Revenue
- OABI $23,027,000.00
- NRO N/A
- Revenue This Year
- OABI N/A
- NRO N/A
- Revenue Next Year
- OABI $48.74
- NRO N/A
- P/E Ratio
- OABI N/A
- NRO N/A
- Revenue Growth
- OABI 6.05
- NRO N/A
- 52 Week Low
- OABI $1.22
- NRO $2.51
- 52 Week High
- OABI $4.87
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- OABI 48.14
- NRO 45.04
- Support Level
- OABI $1.64
- NRO $3.12
- Resistance Level
- OABI $1.76
- NRO $3.22
- Average True Range (ATR)
- OABI 0.10
- NRO 0.04
- MACD
- OABI 0.01
- NRO -0.00
- Stochastic Oscillator
- OABI 23.44
- NRO 39.62
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").